Nuclera Nucleics Stock
Enzymatic DNA synthesis
Sign up today and learn more about Nuclera Nucleics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Nuclera Nucleics Stock
Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.
Funding History
March 2014 | $500K |
---|---|
April 2014 | $100K |
June 2014 | $25K |
April 2015 | $203K |
Press
patents - Apr, 13 2024
Protein purificationpatents - Apr, 13 2024
Creating nucleic acids for in-vitro protein synthesispatents - Apr, 13 2024
Controlled reservoir fillingpatents - Apr, 13 2024
Protein binding assayspatents - Apr, 13 2024
Improved fluorescent proteins